Why the study?
Does acute preprocedural administration of colchicine reduce inflammation and myocardial injury in patients undergoing PCI?
Does acute preprocedural administration of colchicine reduce inflammation and myocardial injury in patients undergoing PCI?
Acute preprocedural colchicine reduces post-PCI inflammatory markers but fails to prevent PCI-related myocardial injury.
Colchicine attenuates post-PCI inflammation without reducing myocardial injury; does not support preprocedural use and questions inflammatory surrogacy.
Acute preprocedural administration of colchicine attenuated the increase in interleukin-6 and high-sensitivity C-reactive protein concentrations after PCI when compared with placebo but did not lower the risk of PCI-related myocardial injury. Registration: URL: https://www.clinicaltrials.gov; Unique Identifiers: NCT02594111, NCT01709981.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2020) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: